GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Regen BioPharma RGBP · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

+33.33%

Close of 5 Nov 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$236,561

FY2016FY2025

Net income

−$1.3m

FY2016FY2025

Free cash flow

−$383,591

FY2016FY2025

Shareholders' equity

−$6.3m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$236,561$236,560$236,560$235,517$171,194$110,000$110,000$100,000$110,000$100,000
Research and development$11,725$153,685$212,297$275,388$36,704$13,286$45,605$374,436$1.1m$671,095
Operating income−$338,540−$418,189−$687,000−$340,000−$201,000−$209,317−$756,785−$1.4m−$2.5m−$3.0m
Net income−$1.3m−$867,252$1.0m$2.2m−$6.8m$2.7m−$2.6m−$4.7m−$5.8m−$3.4m
Diluted earnings per share-0.01-0.050.280.66-2.250.00-4.71-33.39-61.21-35.67

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$274,628$177,611$353,617$559,002$1.2m$123,189$99,087$209,018$944,239$319,356
Cash and short-term investments$716$716$121,037$51,204$727,162——$8,019$269,973$24,822
Total liabilities$6.6m$5.4m$5.5m$8.6m$14.7m$7.5m$11.0m$9.3m$6.2m$906,258
Debt$793,699$814,699$756,204$1.3m$3.6m—$4,978$1.4m$692,654$259,545
Shareholders' equity−$6.3m−$5.2m−$5.1m−$8.0m−$13.5m−$7.3m−$10.9m−$9.1m−$5.3m−$586,902
Shares outstanding100m16m4m3m3m2,260m1m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$383,591−$693,141−$173,917−$606,921−$1.1m$18,645−$481,791−$1.6m−$1.9m−$1.7m
Capital spending——−$3———————
Free cash flow−$383,591−$693,141−$173,920−$606,921−$1.1m$18,645−$481,791−$1.6m−$1.9m−$1.7m
Dividends paid———————−$5,741——

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$59,065$59,065$59,065$59,366$59,065$59,065$59,065$59,366
Operating income$24,528−$153,709−$551,624−$123,055−$40,756−$113,349−$72,537−$86,370
Net income−$637,785$991,927−$967,853−$572,469−$167,292−$19,354−$460,815−$264,899
Diluted earnings per share-0.000.00-0.01-0.01-0.00-0.00-0.03-0.02
Total assets$287,587$260,194$237,076$274,628$196,841$169,482$196,785$177,611
Cash and short-term investments$239$271$4,578$69,555$1,761$1,761$135$716
Debt$924,720$959,146$1.2m$1.2m$1.0m$967,632$873,137$793,699
Shareholders' equity−$5.9m−$5.4m−$6.6m−$6.3m−$5.8m−$5.7m−$5.6m−$5.2m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue0.1%16.5%2.1%
Operating income-0.1%10.1%-16.2%
Net income——-5.4%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-159.9%-188.7%-178.9%-643.2%
Net margin-452.7%117.4%-238.4%-1181.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2022FY2021FY2020
Price to earnings————0.0
Price to sales0.00.00.00.00.9

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-86%29%-80%-73%6501%614348%-93%-94%-38%-53%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-for-1 split · 4 Nov 2024
  • 1500-to-1 reverse split · 6 Mar 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.